John W. Walsh Alpha-1 Home Infusion Act of 2025

119th Congress Introduced by Don Bacon and 49 co-sponsors

The John W. Walsh Alpha-1 Home Infusion Act ensures Medicare and Medicaid cover home infusion therapy for Alpha-1 Antitrypsin Deficiency, improving patient access and care.

Introduced in House

Purpose and Intent

The John W. Walsh Alpha-1 Home Infusion Act of 2025 aims to enhance the accessibility and affordability of home infusion therapy for patients suffering from Alpha-1 Antitrypsin Deficiency (AATD). This legislation seeks to improve the quality of life for individuals with this rare genetic condition by ensuring they have better access to necessary treatments in a home setting, thereby reducing the need for hospital visits.

Key Provisions

The bill includes several significant provisions designed to facilitate home infusion therapy for AATD patients:

Coverage Expansion: The legislation mandates that Medicare and Medicaid programs cover home infusion therapy for AATD, ensuring that patients can receive treatments at home without incurring prohibitive costs.

Provider Reimbursement: It establishes a framework for fair reimbursement rates for healthcare providers who administer home infusion therapy, incentivizing more providers to offer these services.

Patient Education and Support: The bill includes provisions for patient education programs to inform individuals about home infusion therapy options and how to manage their treatments effectively.

Quality Standards: It sets forth quality standards for home infusion services to ensure that patients receive safe and effective care in their homes.

Affected Parties

The primary beneficiaries of HR 2343 include:

Patients with AATD: Individuals diagnosed with Alpha-1 Antitrypsin Deficiency will gain improved access to essential home infusion therapies.

Healthcare Providers: Medical professionals and infusion service providers will benefit from clearer reimbursement guidelines and incentives to offer home-based care.

Families and Caregivers: Families will experience reduced stress and financial burden associated with frequent hospital visits, as patients can receive care in a more comfortable home environment.

Legislative Process and Timeline

Introduced: The bill was introduced in the House on March 25, 2025.

Committee Referral: It has been referred to the Committee on Energy and Commerce and the Committee on Ways and Means for further consideration. The timeline for these committees to review the bill will be determined by the Speaker of the House.

Conclusion

The John W. Walsh Alpha-1 Home Infusion Act of 2025 represents a significant step toward improving healthcare access for patients with Alpha-1 Antitrypsin Deficiency. By facilitating home infusion therapy, the bill aims to enhance patient care, reduce healthcare costs, and improve the overall quality of life for those affected by this condition.

Bill